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OsteoporosisThe turnover of bone is a tightly regulated process between bone formation and resorption to ensure skeletal
homeostasis. This process differs between bone types, with trabecular bone often associated with higher
turnover than cortical bone. Analyses of bone by micro-computed tomography (micro-CT) reveal changes in
structure and mineral content, but are limited in the study of metabolic activity at a single time point, while
analyses of serum markers can reveal changes in bone metabolism, but cannot delineate the origin of any
aberrant ﬁndings. To obtain a site-speciﬁc assessment of bonemetabolic status, bisphosphonate binding kinetics
were utilized. Using a ﬂuorescently-labeled bisphosphonate, we show that early binding kinetics monitored
in vivo using ﬂuorescent molecular tomography (FMT) can monitor changes in bone metabolism in response
to bone loss, stimulated by ovariectomy (OVX), or bone gain, resulting from treatment with the anabolic bone
agent parathyroid hormone (PTH), and is capable of distinguishing different, metabolically distinct skeletal
sites. Using time-lapse micro-CT, longitudinal bone turnover was quantiﬁed. The spine showed a signiﬁcantly
greater percent resorbing volume and surface in response to OVX, while mice treated with PTH showed signiﬁ-
cantly greater resorbing volume per bone surface in the spine and signiﬁcantly greater forming surfaces in the
knee. Correlation studies between binding kinetics and micro-CT suggest that forming surfaces, as assessed by
time-lapse micro-CT, are preferentially reﬂected in the rate constant values while forming and resorbing bone
volumes primarily affect plateau values. Additionally, we developed a blood pool correction method which
now allows for quantitative multi-compartment analyses to be conducted using FMT. These results further
expand our understanding of bisphosphonate binding and the use of bisphosphonate binding kinetics as a tool
to monitor site-speciﬁc changes in bone metabolism in vivo.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Bone turnover is tightly regulated by osteoblasts and osteoclasts,
and is essential for maintaining the integrity and adaptation of the
skeleton. This process is both spatially and temporally regulated,
ensuring equal bone resorption and new bone formation, in order to
maintain bone mass [13,29]. Disruption of this coupled process can
lead to abnormal bone loss or gain, both with severe ramiﬁcations.
Remodeling is also essential for the turnover of aged bone, which
removes microfractures and maintains the mechanical competence ofElmer in the form of discounted
24118 Kiel, Germany.
. This is an open access article underthe bone tissues throughout the body [20]. Long and vertebral bones
differ in their composition of trabecular and cortical bone, and in their
levels of metabolic activity. While both cortical and trabecular bones
require constant remodeling to maintain the integrity of the skeleton,
trabecular bone resorption additionally contributes, to a greater extent,
to blood calcium homeostasis, resulting in a higher level of metabolic
activity [5,24].
While longitudinal analyses of bone bymicro-computed tomography
(micro-CT) provide detailed insights into structural adaptations, as
well as changes in bone mineral content over time, such studies require
weeks or months in mice before changes are observed and the assess-
ment of the short-term changes in metabolic status of these bones
remains difﬁcult. Recent method developments have allowed the
assessment of bone formation and resorption rates in vivo [15,28], but
fail to show the instantaneous state of bone metabolism. In contrast,
analyses of serum markers can provide insight into the current
metabolic status of the skeleton, but fail to differentiate the individualthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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F-ﬂuoride positron emission tomography (PET) has proven to be a
feasible tool for metabolic monitoring [22]. However, in mice, only
cases of extreme changes in bone activity (complete fracture or
cancer-induced severe osteolysis) have been successfully documented
[1] and require the repeated injection of radioactive material. To this
end, new methods are required for the site-speciﬁc monitoring of
bone metabolic status.
Because of their anti-resorptive properties, bisphosphonates are in
widespread clinical use in patients with excessive bone loss (i.e. osteo-
porosis, tumor osteolysis) [17]. Recent research has also exploited the
bisphosphonates' ability to bind bone mineral with high afﬁnity as a
bone metabolic marker rather than as a therapeutic agent. Conjugation
of bisphosphonates with ﬂuorescent dyes is currently under great
scrutiny to help characterize bisphosphonate binding [11,27], as well
as in the use as a bone-speciﬁc turnover marker [11,14]. While early
works focused on bisphosphonate binding days after injection, new
data suggests that monitoring the kinetics of early binding (as little as
5 min after injection) may provide additional information about the
metabolic status of the bone [30]. One limitation in previous in vivo
kinetic assessments has been the lack of indicators of blood pool
bisphosphonates available for bone binding, which are used in more
reﬁned, quantitative, multi-compartment analyses commonly seen
in the context of radiolabeled bisphosphonates [18]. Recent radionu-
clide studies in humans have also suggested that signiﬁcant overall
changes in skeletal activity, such as those seen in the case of
treatment with parathyroid hormone (PTH), may alter the plasma
time-activity curve [2]. This effect would alter both the rate and total
binding values of a ﬂuorescently-labeled bisphosphonate as discussed
previously [30].
The purpose of this study was to assess whether the binding kinetic
characteristics previously observed in the proximal tibia could be
distinguished from other, metabolically distinct skeletal sites and to
compare the relationship between observed binding kinetic parameters
and longitudinal changes in bone structure, as assessed by time-lapse
micro-CT [15]. Additionally, we have generated a blood pool correction
factor allowing multi-compartment, quantitative kinetic analyses to be
conducted using a modiﬁed Patlak's method [18], accounting for
changes in the quantity of bisphosphonate probe available for binding.Materials and methods
Animals
12 week old female, CD-1 nude mice were purchased from
Charles River (Wilmington, MA). All animals were kept in a temper-
ature and humidity-controlled environment, with a 12 h light/dark
cycle, and access to food and water ad libitum. Animal experiments
and care were in accordance with the guidelines of institutional
authorities and approved by the Ethics Committee for Animal
Experiments at the Christian-Albrechts-Universität-zu-Kiel [V 312-
72241.121-33]. Mice were anesthetized with intraperitoneal
injections of 80 mg/kg ketamine (Aveco Pharmaceutical, IA) and
10 mg/kg xylazine (Rugby Laboratories, GA). For long-term
anesthetization, additional administration of ketamine and xylazine at
half dosewas administered upon initial signs ofmousewaking. Animals
were separated into 3 groups (n = 9/group): i) non-operated, control
animals, ii) ovariectomized (OVX) animals, imaged 3 days (short-
term) and 14 days (long-term) after OVX, and iii) PTH-treated mice,
which were subjected to OVX, then received daily PTH injections for
3 days beginning 11 days post-surgery (total of 14 days OVX and
3 days PTH treatment) as previously described [30]. Animals were
ovariectomized via their dorsal side. Human parathyroid hormone
fragment 1–34 (Sigma-Aldrich, MO) was given subcutaneously at a
dose of 100 μg/kg daily.Bisphosphonate binding kinetics
Anesthetizedmicewere injected intravenously with 100 μl PBS con-
taining 2 nmol of dissolved OsteoSense750, a ﬂuorescently-conjugated
pamidronate derivative [32]. For all in vivo, quantitative assessments
of bisphosphonate binding, anesthetizedmicewere imaged immediate-
ly following injection and every subsequent ~15 min interval for
210 min by FMT using the 750 nm channel of the FMT2500LX (Perkin
Elmer, MA, USA). Images were reconstructed and VOIs of equal
dimensions were positioned using the photographic image around the
proximal tibia region, as well as the L1 and L2 vertebrae, and quantiﬁed
using the TrueQuant software. Kinetic curves were generated using the
average ﬂuorescent intensity of either the proximal tibiae or vertebral
regions over time using one-phase association curves, with Y0 values
constrained to zero, generated from Prism (version 5, GraphPad
Software, CA). Graphs show only the ﬁrst 100 min of imaging to more
clearly illustrate changes in initial binding kinetics, though all time
points were used to generate binding kinetic curves. Due to the low
resolution of FMT, proximal tibia VOIs may also contain ﬂuorescence
of the distal femur. For this reason, this region is henceforth referred
to as the knee region.
Micro-CT analysis
All animalswere scanned bymicro-CT prior to treatment to establish
baseline bone parameters. Changes in bone mineral and structure
resulting from OVX or PTH treatment were characterized from micro-
CT assessment of skeletal changes in vivo. Anesthetized mice were
placed in full-body holders and the tibiae aligned by visual inspection.
Scans were made using a Scanco vivaCT 40-micro-CT (Brüttisellen,
Switzerland) at an isotropic voxel size of 19 μm (70 kVp, 114 μA,
250 ms integration time, 1000 projections on 180° 2048 CCD detector
array, cone-beam reconstructionwith a radiation dose of approximately
520 mGy (CTDIair)). PTH-treated mice were additionally scanned by
micro-CT after 14 days of intermittent PTH treatment to capture
long-term bone changes. Three volumes of interest (VOIs) were
selected, one for the vertebra, as well as one each for the epiphyseal
and metaphyseal region of the proximal tibia (to exclude the growth
plate region). Contours along the periosteal surfaces were drawn
encompassing either 60 slices (1.05 mm) of the L1 vertebra, starting
at the beginning of trabecular bone within the spinal body, 50 slices
(0.875 mm) beginning at the proximal tip of the tibia epiphyseal
trabecular bone, or 50 slices (0.875 mm) beginning just distal to the
tibial growth plate, all extending in the distal direction. Baseline VOIs
were transferred to the follow-up scans using an image registration
approach to ensure analysis of consistent VOIs at each time point [3].
Bone mineral density (BMD) was calculated from the greyscale micro-
CT images (Image Processing Language (IPL) v5.15, ScancoMedical,
Brüttisellen, Switzerland) as the total bone mineral content within the
contour divided by the contour volume. Localized bone formation and
resorption was determined from the time-lapsed micro-CT images after
registration using programswritten in IPL for the registration, andMatlab
(R2010b; Mathworks, Natick, MA, USA) for the quantiﬁcation of bone
turnover, following similar procedures as previously described [28].
Brieﬂy, a three-color image was produced from the overlaid follow-up
and baseline images after a threshold (23% of maximal greyscale value)
was applied. From this image, the volume of formed, resorbed and
quiescent bone could be determined. The contact surfaces between
the colored regions were used to calculate the formed and resorbed
surface area.
Soft tissue–blood pool correlation
VOIs were placed over soft tissue regions in the abdomen and the
corresponding ﬂuorescence quantiﬁed. Kinetic curves for the soft tissue
analysis were generated in Prism using one-phase exponential decay
173R.J. Tower et al. / Bone 74 (2015) 171–181curves, with the non-speciﬁc binding at inﬁnite times (NS) values
constrained to N0. A standard curve was generated by direct addition
of known concentrations of OsteoSense750 to serum collected from
non-injected mice and subsequently scanned by the Odyssey ﬂuores-
cent scanner. For comparison of soft tissue ﬂuorescence (assessed by
FMT) and serum bisphosphonate levels, mice were imaged by FMT 1,
15, 30, 45 and 60 min after injection, followed by immediate blood
collection from the tail vein. Whole blood was separated at 3000 g for
10min and serum isolated. Serumwas scanned on the Odyssey ﬂuores-
cent scanner and compared to standard curve ﬂuorescent readings to
determine bisphosphonate concentrations.Statistical analysis
All statistical analyses were conducted using Prism. Binding rate
constants (k) and plateau values were calculated for curves from
the line of best ﬁt for each mouse using the formula: Y = Y0 +
(Plateau− Y0)(1− exp−Kx), where Y = ﬂuorescence at time x, Y0 =
the ﬂuorescence at time 0, and x = time in minutes. The plateau,
reﬂecting the maximum binding ﬂuorescence expected as time
approaches inﬁnity, and the rate constant, reﬂecting the rate at which
the curve approaches its plateau value, was multiplied to generate a
plateau-weighted (Pw) rate constant for each mouse representing
overall curve characteristics. For soft tissue analysis, Y0 (ﬂuorescent
signal at time zero), NS (ﬂuorescent signal as time approaches inﬁnity)
and K (clearance rate) values were calculated for curves from the line of
best ﬁt for each mouse using the formula: Y = (Y0 − NS)−kx + NS.
Comparison between groups was made using two-sample t-tests using
the Welch–Satterthwaite method to avoid the assumption of equal vari-
ances. Comparison between knee and spine values within the same
mouse was made using paired t-tests. Time-lapse micro-CT statistics
were calculated using a two-way ANOVA. Interaction between binding
kinetic and time-lapse micro-CT parameters was assessed by the proba-
bility of the slope of the linear correlation being equal to zero using
Prism. p values of b0.05 were considered to be statistically signiﬁcant.
KBone was determined using a modiﬁed Patlak's method as previously
described [18]. In short, average KBone values were determined by calcu-
lating changes in area-under-the-plasma-clearance-curve (AUC) and
whole-body retention (WBR) values generated for each mouse between
each FMT imaging time point. Plasma concentrations and bone uptake
(BU) values at each time point were determined by the formulas:
plasma½  ¼ soft tissue fluorescence pmolð Þ
injected fluorescence pmolð Þ  VOI volume mlð Þ
BU ¼ bone VOI fluorescence pmolð Þ mass of mouse kgð Þ
injected fluorescence pmolð Þ  VOI volume mlð Þ :Results
Vertebrae bisphosphonate uptake kinetics are altered in ovariectomized
and PTH-treated mice
Average ﬂuorescence of the L1 and L2 vertebraewas quantiﬁed from
injected mice and subjected to nonlinear regression analysis (Fig. 1A).
Vertebral ﬂuorescence showed signiﬁcant reductions in binding
plateaus, rate constants and Pw rate constants after short-term OVX
when compared to control groups, with further signiﬁcant reductions
in long-term OVX mice (Figs. 1B–D), while PTH-treated mice showed
signiﬁcant increases in binding plateau, rate constant and Pw rate
constant values compared to untreated OVX controls.Fluorescent bisphosphonate binding kinetics reveal differential changes in
uptake parameters in the knee and spine
To examine region-speciﬁc differences in uptake, changes in ﬂuores-
cent bisphosphonate kinetic parameters obtained for the knee (as previ-
ously published [30]) and spine for each group were compared. Overall,
changes in kinetic parameters were similar for both the knee and spine
in response to OVX. No signiﬁcant differences in percent change in pla-
teau values were observed between short and long-term OVX, relative
to control, for either the knee or the spine (Fig. 2A). In contrast, while
both the spine and the knee showed signiﬁcant reductions in the rate
constant, the changes observed in the kneewere slightly but signiﬁcantly
greater than those observed in the spine after long-term OVX (Fig. 2B).
Both the knee and the spine showed reductions in the Pw rate constant,
with signiﬁcantly greater reductions after long-term OVX as compared
to short-term (Fig. 2C), but no signiﬁcant differences were observed be-
tween regions. In response to PTH treatment of OVX mice, clear differ-
ences were observed in the rate constant and plateau values between
the knee and spine regions. The spine showed a signiﬁcantly greater in-
crease in the binding plateau, while the knee showed a signiﬁcantly
greater increase in rate constant values in OVX mice treated with PTH,
relative to untreated OVX controls (Figs. 2D and E). Overall, no signiﬁcant
changes in the Pw rate constants were observed between the knee and
the spine in response to PTH treatment (Fig. 2F).
To delineate the biological signiﬁcance of the observed changes in
binding plateau and rate constant values, micro-CT analyses were con-
ducted to monitor changes in BMD, bone microstructure and turnover
in the knee and spine. Bone loss expected as a result of OVX was con-
ﬁrmed by BMD assessment which showed signiﬁcantly reduced values
in both the spine and knee after long-term OVX (data not shown) and
serummarker analyses [30]. Baseline and follow-up scanswere overlaid
to ensure analyses of similar regions and to visualize regions of bone for-
mation and resorption which occurred between imaging time points
and pre-OVX baseline scan (Fig. 3A). Images were used to quantify
bone forming and resorbing surfaces (Figs. 3B and D) and volumes
(Figs. 3C and E). Time-lapse micro-CT showed a trend towards in-
creased resorbing surfaces (p = 0.0683) and signiﬁcantly greater re-
sorbed bone volume in the tibia between short-term and long-term
OVX. Relative to the tibia, the spine showed a trend towards an in-
creased percent resorbing surface after short-term (p = 0.0926) and
long-term (p = 0.0771) OVX, as well as signiﬁcantly greater resorbed
bone volume after short-term and long-term OVX. A two-way ANOVA
was conducted to determine overall effects of skeletal site and length
of OVX on time-lapse micro-CT parameters (Table S1). Neither the
skeletal site (tibia vs spine), nor the duration of OVX (day 3 vs day 14)
had a statistical impact on bone forming surfaces or volumes. In
contrast, resorbing surfaces and volumes both showed a signiﬁcant
dependence on both the skeletal site assessed, as well as the duration
of OVX.
Micro-CT analyses were next conducted on mice treated with PTH.
Because BMD values failed to show any signiﬁcant changes after
3 days of PTH treatment, an additional follow-up scan was taken after
14 days of PTH treatment, which showed a signiﬁcant increase in knee
BMD (data not shown) and signiﬁcantly increased bone metabolic
serum markers [30] and likely represents changes in bone structure
which would result from the day 3 metabolic bone statuses. Baseline
and follow-up scans were overlaid to ensure analyses of similar regions
and to visualize regions of localized bone formation and resorption in
the vertebral and tibial VOIs (Fig. 4A) and to quantify bone forming
and resorbing surfaces (Figs. 4B and D) and volumes (Figs. 4C and
E) which occurred relative to pre-treatment baseline scan. Both the
tibia and spine showed signiﬁcantly greater bone forming surfaces
and volumes between early and long-term PTH treatment, with the
tibia containing signiﬁcantly greater forming surfaces than the spine
after long-term PTH treatment. In contrast, the spine contained signiﬁ-
cantly greater bone resorbing surfaces and volumes than the tibia
Fig. 1.Ovariectomy and treatment with PTH results in signiﬁcantly altered binding kinetic parameters of a ﬂuorescently-conjugated bisphosphonate. Time resolved bone binding pattern
of ﬂuorescently-labeled bisphosphonate in L1 and L2 (A). Long-term ovariectomized mice showed signiﬁcantly reduced binding plateaus (B), rate constants (C) and plateau-weighted
(Pw) rate constants (D) compared to short-term OVX mice, which in turn showed signiﬁcant reductions in all parameters compared to control mice, while treatment of mice with
PTH for 3 days resulted in values comparable to control mice and binding kinetic parameters signiﬁcantly greater than OVXmice. Dotted lines represent 95% conﬁdence interval of ﬁtted
curve. Graphs represent average values ± SD. (**p b 0.01, ***p b 0.001) (n = 9).
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ses of time-lapse micro-CT parameters revealed that both the skeletal
site and the duration of PTH treatment (day 3 vs day 14) signiﬁcantly
affected the bone forming surfaces, while only the length of PTH
treatment affected bone formation volumes (Table S2).
Binding kinetic parameters correlate with changes in bone formation and
resorption
In order to determine which aspects of bone formation and resorp-
tion are reﬂected in each bisphosphonate binding kinetic parameter,
correlation studies were conducted between rate constant, plateau
and Pw rate constant values determined by FMT and time-lapse
micro-CT-derived bone forming and resorbing surfaces (Figs. 5A
and C) and volumes (Figs. 5B and D), and their interaction assessed
(Table 1). Percent forming surfaces, assessed by time-lapse micro-CT,
showed signiﬁcant correlationswith rate constant and Pw rate constant
values, assessed by FMT binding kinetics, while percent forming and
resorbing bone volumes signiﬁcantly correlated with plateau values.
Soft tissue ﬂuorescence of the abdominal region correlates with serum
levels of bisphosphonate
To assess the blood pool levels of bisphosphonate available for
binding over time, abdominal soft tissue ﬂuorescence was measured(Fig. 6A) and subjected to nonlinear regression analysis (Fig. 6B).
Both short and long-term OVX mice showed signiﬁcantly greater
maximum tissue ﬂuorescence than control mice, while treatment
with PTH signiﬁcantly reduced maximum ﬂuorescence back to levels
comparable with control mice (Fig. 6C). Ovariectomy also resulted in
increased minimum ﬂuorescence values with long-term OVX mice
having signiﬁcantly greater values than that of control mice.
Treatment with PTH resulted in a signiﬁcant decrease in minimum
ﬂuorescence values to levels consistent with control mice (Fig. 6D).
Both short and long-term ovariectomy resulted in signiﬁcantly
decreased soft tissue clearance from control mice, while PTH
treatment resulted in a signiﬁcant increase in the clearance rate
compared to untreated long-term OVX (Fig. 6E). A standard curve
(Fig. 6F) was used to calculate serum level bisphosphonates in
imaged mice and compared to soft tissue ﬂuorescence detected
by FMT. A strong correlation (R2 = 0.8621) was found between
bisphosphonate concentrations, determined by FMT soft tissue
ﬂuorescence, and ex vivo serum analysis (Fig. 6G). Using a modiﬁed
Patlak's method, ovariectomized mice showed signiﬁcantly
reduced KBone values as compared to control mice in both the
knee and spine regions, while PTH-treated mice showed signiﬁ-
cantly increased KBone values from untreated OVX controls
(Fig. 6H). Analyses also show signiﬁcantly greater KBone values in
the spine for each test group relative to the corresponding knee
values.
Fig. 2. Spine and knee regions show differential changes in bisphosphonate binding kinetics in response to ovariectomy and PTH treatment. Analyzing changes in binding kinetic param-
eters in response to ovariectomy, both the knee and spine showedno signiﬁcant differences in the change between short and long-termOVX (A), but did show a signiﬁcant increase in rate
constant values (B). Both regions showed signiﬁcant changes in Pw rate constant values between short and long-termOVXmice (C). In response to PTH treatment in OVXmice, the spinal
region showed signiﬁcantly greater changes inplateau binding values (D),while the knee region showed signiﬁcantly greater changes in rate constant values (E), relative to untreatedOVX
controls. Pw rate constant values showed no signiﬁcant differences between the knee and spine region after PTH treatment (F). Dotted lines represent 95% conﬁdence interval. Graphs
represent average values ± SD. (*p b 0.05, **p b 0.01, ***p b 0.001) (n = 9).
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Fig. 3. Bone loss associated with ovariectomy preferentially affects the spine. (A) In vivomicro-CT was used to analyze changes in bone microstructure in the L1 vertebrae and the tibia.
Color-coded subtraction images show regions of bone formation (orange) and bone resorption (blue). Time-lapse micro-CT was used to quantify bone forming surfaces and volumes (B
and C), as well as resorbing bone surfaces and volumes (D and E) at each time point relative to its baseline scan prior to OVX. The spine contained consistent levels of bone resorbing vol-
umes after both short-term and long-termOVX, signiﬁcantly greater than resorbing volumes observed in the tibia, while the tibia showed a signiﬁcant increase in resorbing bone volume
from short-term to long-term OVX. Two-way ANOVA analyses (Table S1) revealed that, although neither skeletal site nor duration of OVX signiﬁcantly affected bone forming surfaces or
volume, both bone region and length of OVX signiﬁcantly affected bone resorption surfaces and volume. Graphs represent average values ± SD. (*p b 0.05) (n = 9).
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In this study, we demonstrate that ﬂuorescent bisphosphonates
show consistent patterns of binding at both the vertebra and long
bones in response to OVX or PTH treatment. Furthermore, we show
that changes in binding kinetic parameters were found to mirror later
changes observed bymicro-CTmethods. These binding kinetic parame-
ters reﬂect the site-speciﬁc, variations observed in response to changesinmetabolic status.We have additionally shown that soft tissue ﬂuores-
cence, as assessed by in vivo FMT, correlates with serum levels of free
bisphosphonate and can be used as a tool to monitor the changes in
blood pool levels of bisphosphonates over time. Combining our uptake
parameters of both the knee and spine regions with our soft tissue
blood pool measure, we have generated KBone values for each mouse
using a modiﬁed Patlak's method. Values obtained from this method
show signiﬁcant reductions in bisphosphonate uptake by the bone in
Fig. 4. Treatment with PTH results in signiﬁcant changes in bonemicrostructure. In vivomicro-CT of the L1 vertebra and the knee over 14 days of PTH treatment (A). Time-lapsemicro-CT
was used to quantify bone forming surfaces and volumes (B and C), as well as resorbing bone surfaces and volumes (D and E) at each time point relative to its baseline scan before com-
mencement of PTH treatment. Both the tibia and spine showed signiﬁcant increases in bone forming surfaces and forming volumes after prolonged PTH treatment, with the tibia contain-
ing signiﬁcantly greater bone forming surfaces than the spine after long-term PTH treatment. In contrast, the spine showed signiﬁcantly greater levels of bone resorbing surfaces and
volumes compared to the tibia. Two-wayANOVA analyses (Table S2) revealed thatwhile only duration of PTH treatment affected bone formation volumes, both skeletal site and treatment
length signiﬁcantly affectedbone forming surfaces. In regard to bone resorption, only skeletal site, and not duration of PTH treatment,was found to signiﬁcantly affect resorbing volumes or
surfaces. Graphs represent average values ± SD. (*p b 0.05, **p b 0.01, ***p b 0.0001) (n = 9).
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Fig. 5. Linear correlations between binding kinetic and time-lapse micro-CT parameters. Binding kinetic parameters, assessed by in vivo FMT, for both the spine and knee regions, were
subjected to linear regression analyses with % forming (A) and resorbing (C) surfaces and % forming (B) and resorbing (D) volumes as assessed by time-lapse micro-CT.
178 R.J. Tower et al. / Bone 74 (2015) 171–181response to ovariectomy and signiﬁcant increases in bone uptake after
PTH treatment.
As has been previously described for the knee region, short-term
ovariectomized mice showed signiﬁcantly reduced plateau, rate
constant and Pw rate constant values compared to control mice, with
further signiﬁcant reductions observed in all parameters after long-
term OVX in the spine. Conversely, treatment with PTH was found to
signiﬁcantly increase all binding parameters compared to untreated
controls. Based on micro-CT morphometry, combined with the ob-
served changes in binding kinetics of the spine and knee region in
response to OVX and PTH treatment, bone surface and metabolic status
play an important role in both plateau and rate constant binding param-
eters. In response to treatmentwith PTH, we observed a preferential in-
crease in rate constant within the knee and binding plateau within the
spine. This corresponded to preferential increases in bone forming
surfaces in the knee and elevated levels of bone resorption surfaces
and volumes in the spine. This data suggests a relationship between
rate constant and plateau values and changes in metabolic activity
which ultimately gives rise to bone loss/apposition. Though rate
constant and plateau values are interdependent, correlation studies
with time-lapse micro-CT, which assesses localized changes in bone
microstructure [12,15], support a preferential interaction between
bone apposition surfaces and rate constant values, as well as bone lossTable 1
Rate constant values reﬂect changes in forming surfaces while plateau values reﬂect
changes in bone formation and resorption volumes. Linear correlations between binding
kinetic and time-lapse micro-CT parameters shown in Fig. 5 were assessed for their inter-
action. Values represent: Signiﬁcance of the linear correlation/probability that slopes are
equal to zero. ns = not signiﬁcant.
Rate constant (k) Plateau Pw rate constant
% forming surface 0.05/0.0174 ns/ns 0.01/0.0014
% resorbing surface ns/ns ns/ns ns/ns
% forming volume ns/ns 0.05/0.0430 ns/ns
% resorbing volume ns/ns 0.01/0.0066 ns/nsand apposition volumes and plateau values. The fact that binding kinet-
ics in the knee and spine differ in response to PTH treatment suggest
that this kinetic monitoring has the ability to distinguish between
these metabolically distinct sites with a high degree of sensitivity. It is
important to note that, because micro-CT provides only a snap shot of
bone structure, time-lapse micro-CT analyses may underestimate the
amount of bone forming volumes and surfaces in regions where new
bone formation occurs over top of resorbed areas, but has not deposited
sufﬁcient mineral to overcome the mineral lost by previous resorption.
Histological conﬁrmation will be required to correlate metabolically
actively forming and resorbing surfaces with bisphosphonate uptake.
Nevertheless, micro-CT has previously been shown to correlate with
dynamic histomorphometry in mice [28].
Previous works have demonstrated a preferential uptake of
bisphosphonates by newly mineralized bone, and by active remodeling
surfaces compared to quiescent bone surfaces [27,30]. Taken together,
we propose a hierarchical model of bone bisphosphonate uptake from
high uptake, newly mineralized bone, to medium uptake, newly
exposed/resorbing bone, to low uptake, quiescent bone surfaces. Using
these criteria, treatment with PTH results in increased high uptake
bone surfaces within the knee region, resulting in rapid uptake shortly
after injection, while the spine shows increased accumulation of both
high and medium uptake bone, resulting in increased uptake rates and
plateau values. While the amount of high uptake, newly mineralized
bone is dependent on the osteoblast activity, the amount of newly ex-
posedmineral will be dependent on the osteoclasts andwill be affected
both by the number of osteoclasts as well as the depth of the resorbing
pits. Though the preferential uptake of bisphosphonates by newly de-
posited minerals has previously been suggested to reﬂect the presence
of amorphous, higher afﬁnity calcium phosphate present in newly
forming bone as compared to the lower afﬁnity crystalline minerals
present in fully mineralized bone [8,30], both quiescent and resorbed
surfaces are comprised of fully mineralized bone. Reduced exposure
and/or binding of the bone mineral, potentially limited by bone lining
cells or secreted extracellular matrix components present on quiescent
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tial uptake of bisphosphonates from the blood. It has also been
suggested that crystal size inversely correlates with the speciﬁc area
available for bisphosphonate binding, with newly deposited minerals
being smaller than those found in fully mineralized bone [10,27]. As a
result, high turnover regions will also be associated with smaller crystal
sizes, greater speciﬁc area available for binding, and subsequently,
higher bisphosphonate uptake than low turnover bone.
Finally, we have demonstrated that time-related reductions in
bisphosphonate ﬂuorescence from within the abdominal soft tissue
show signiﬁcant reductions in both the extent and rate of clearance in
response to OVX and signiﬁcantly greater clearance kinetics in
PTH-treated mice compared to untreated controls. These results are
consistent with the observed changes in bisphosphonate bone uptake
in that decreased bone uptake, in the case of OVX, would result in
delayed blood clearance while increased bone uptake, observed in
PTH-treated mice, would result in increased blood pool clearance. We
also showa strong correlation between soft tissueﬂuorescence assessed
by in vivo FMT and serum levels of free bisphosphonate. Using soft tissue
ﬂuorescence as a blood pool correction, modiﬁed compartment model
Patlak's calculations were conducted to assign quantitative values of
bisphosphonate bone uptake. Results show that ovariectomy gives rise
to signiﬁcant reductions in KBone values while treatment with PTH
shows signiﬁcant increases in this parameter. Additionally, Patlak's cal-
culations also showed signiﬁcantly greater KBone values for the spine in
each test group relative to corresponding values observed in the knee,
similar to results observed in humans using 18F-ﬂuoride PET comparing
the vertebra to the humerus [6]. This has previously been explained by
greater tracer delivery to the spine, accounted for by greater regional
blood ﬂow [22]. Because these values are derived from both blood and
bone values, KBone values reﬂect the accumulation of bisphosphonates
on the bone adjusted for the clearance of available unbound probe
from the blood and thus, KBone values should better approximate
changes in bone metabolism. In our models of relatively short term
OVX or treatment with PTH, minimal changes in body weight, renal
function or blood ﬂow are expected to occur, minimizing the overall
beneﬁt received with this modiﬁed multi-compartment analysis.
However, while the resolution of FMT does not permit the evaluation
of site-speciﬁc blood ﬂow, this general blood pool correction factor
should prove useful in mouse models in which signiﬁcant changes in
body mass or renal function occur, such as the case in tumor models
and some therapeutic treatments, and help overcome some bias in
bone binding kinetics resulting from the uptake of bisphosphonates
by other skeletal sites as has previously been observed in treated
patients [2].
It remains unclear why micro-CT results demonstrated a greater re-
sponse to PTH in the knee compared to the spine. Previous works have
suggested competing perspectives on the effects of PTH treatment on
spine and tibia bone mineral changes [9,33]. It is possible that because
of the site of injection and the dosing administered in this study, bone
changes in the spine reﬂect more a continuous PTH-dosing model in
which the anabolic effects are replaced with signiﬁcant upregulation
in bone remodeling with no net bone mineral increase [16]. Other
works have also suggested that different skeletal sites may be
comprised of functionally distinct cell populations which respond at
different rates and to different extents to anabolic therapy [23]. ThisFig. 6.Abdominal soft tissueﬂuorescence correlateswith serumbisphosphonate levels and show
FMT imageswas quantiﬁed in regions devoid of bone (A) and subjected to nonlinear regression
tissue ﬂuorescence compared to control mice, while treatment with PTH signiﬁcantly reduced
sulted in signiﬁcantly decreased clearance rates of soft tissueﬂuorescencewhile treatmentwith
edOVX controls. (F) A standard concentration curve ofﬂuorescent bisphosphonates in serumw
mice. Fluorescence in the soft tissue region, determined by FMT imaging, and serum levels of ﬂ
actual serum levels of bisphosphonate (G). Using a modiﬁed Patlak's method (H) analysis show
sponse to PTH treatment for both the knee and spine regions (*). Analyses also show signiﬁcant
represent 95% conﬁdence interval. Graphs represent average values ± SD. (*,#p b 0.05, **,##pidea is supported by the fact that, while both the knee and spine regions
show relatively similar increases in bone forming surfaces and volumes,
relative to OVX controls, the knee shows substantially greater
reductions in bone resorbing volumes and surfaces than were observed
in the spine. As a result, the overall bone metabolic activity (bone
formation and resorption) is greater in the spine than the knee. This is
consistent with micro-CT and KBone values in which the spine shows
signiﬁcantly greater bone turnover (forming and resorbing bone
volume) and greater uptake of bisphosphonate relative to the knee
region. It has also been noted that PTH treatment tends to enhance
bone formation at sites of stress [26] and this effect may be mediated
through sclerostin [21]. Nude mice used in this study are also T cell-
deﬁcient, which have previously been shown to play a role in stimulat-
ing both osteoclastogenesis and osteoblast differentiation [4,19,25,31].
It would be of great interest to determine which, if any, of these factors
contribute to the differential responses observed to PTH treatment be-
tween the knee and the spine in this study and other studies published
in mice, rats and humans. It is also possible that, because kinetic
analyses were done after a relatively short time period after the
beginning of PTH treatment, the knee region, and predominantly the
actively-modeling trabecular regions distal to the growth plate, are
more rapidly responsive and thus, show more signiﬁcant changes in
BMD values relative to the spine.
Overall, these methods show great utility in using bisphosphonate
binding kinetics and time-lapse micro-CT as in vivo tools for assessing
metabolic activity in a range of potential bone-loss and bone-gain
models.Wewere able to show bonemetabolism, as assessed by binding
kinetics, varies between skeletal sites. We also provide evidence that
these differences may be due to changes in bone surface properties, as
illustrated by correlation with time-lapse micro-CT analyses. Both
methodswere also able to distinguish differential responses to bone an-
abolic treatment suggesting utility inmonitoring site-speciﬁc responses
to novel therapeutic interventions. With the addition of a blood pool
correction and multi-compartment analyses, the binding kinetics
assay now accounts for biases introduced by off-site uptake (both soft
tissue and other, non-measured skeletal sites) as well as conditions
which may result in delay clearance of free bisphosphonates from the
blood pool (i.e. renal impairment).
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bone.2015.01.009.Acknowledgments
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